Primary completion date for the onCARlytics OASIS trial is...

Primary completion date for the onCARlytics OASIS trial is estimated to be in September 2024 with trial completion for September 2025.

Primary completion for the Vaxinia MAST trial is scheduled for December 2024 with trial completion for January 2025.

We’ve also been advised there will be data cuts along the way to coincide with information provided to major conferences.

I’m really confused by all the comments of some posters who seem to be expecting an imminent “something big” about the CF33 platforms, when it has been made clear what the timelines are.

HER-Vaxx is the closest product to monetisation and possibly the one referred to by LC recently. Apart from perhaps PD1-Vaxx, the other products are far too early in clinical trials to derive appropriate value for shareholders in any licensing deals and given IMU has the funding, there is little incentive to sign low value deals.

Whilst it would be great to see the share price soar past $1-2 per share, I don’t see that happening anytime before the phase 1 trial results have been released, and even then it’s probably a stretch before an announcement giving a solid timeline towards revenue.